Palvella Therapeutics (PVLA) Stock Price Target 2026

The average analyst price target for Palvella Therapeutics is $173.42, 0.3% above the current price. Of 17 analysts, 17 rate it Buy. Targets range from $38 to $250. The latest change came on Nov 9, 2026, when Canaccord Genuity raised its price target on Palvella Therapeutics from $232 to $243 and kept a Buy rating.

The Average Analyst Price Target for Palvella Therapeutics is $173.42.

Price Target Range — 9 Quarters

Analyst Consensus — 17 Analysts

1S.Buy

16Buy

Consensus RatingBuy# Analysts17Avg. Consensus PT$173.42Upside to Avg. PT+0.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Palvella Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 9, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$232→$243
Nov 6, 2026	Oppenheimer	Trevor Allred	PT Raise	Outperform	$210→$232
Oct 28, 2026	Chardan Capital	Gautam Chukka	Maintained	Buy	$240
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 12, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Cut	Buy	$270→$246
Sep 21, 2026	Chardan Capital	Gautam Chukka	Maintained	Buy	$240
May 21, 2026	Stephens & Co.	Sudan Loganathan	Maintained	Overweight	$220
May 21, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$240
May 12, 2026	Stephens & Co.	Sudan Loganathan	Initiate	Overweight	$220
Mar 31, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$210→$240
Mar 24, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$255→$270
Mar 16, 2026	Chardan Capital	Geulah Livshits	Maintained	Buy	$210
Feb 25, 2026	Mizuho	Graig Suvannavejh	PT Raise	Outperform	$205→$250
Feb 25, 2026	BTIG	Jeet Mukherjee	PT Raise	Buy	$192→$215
Feb 24, 2026	Chardan Capital	Geulah Livshits	PT Raise	Buy	$174→$210
Feb 24, 2026	HC Wainwright & Co.	Andrew S. Fein	PT Raise	Buy	$200→$255
Jan 29, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$192
Jan 16, 2026	BTIG	Jeet Mukherjee	Maintained	Buy	$192
Jan 7, 2026	Mizuho	Graig Suvannavejh	Initiate	Outperform	$205
Dec 16, 2025	Truist Securities	Danielle Brill	PT Raise	Buy	$105→$190

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243

Canaccord Genuity analyst Whitney Ijem maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $232 to $243.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232

Oppenheimer analyst Trevor Allred maintains Palvella Therapeutics (NASDAQ:PVLA) with a Outperform and raises the price target from $210 to $232.

Benzinga Newsdesk

PRO
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.

Benzinga Newsdesk

Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday

Analysts raised targets for CRBG, MTN, CRM and FSLR, while cutting targets for PVLA, SPOT and AMZN; CRM and FSLR were upgraded.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.

Benzinga Newsdesk

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.

Benzinga Newsdesk

Palvella Therapeutics Inc

Palvella Therapeutics (PVLA) Stock Price Target 2026

The Average Analyst Price Target for Palvella Therapeutics is $173.42.

Latest Upgrades and Downgrades for Palvella Therapeutics Stock

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243

PRO
Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232

PRO
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

People Also Watch

People Also Watch

Palvella Therapeutics Inc

Palvella Therapeutics (PVLA) Stock Price Target 2026

The Average Analyst Price Target for Palvella Therapeutics is $173.42.

Latest Upgrades and Downgrades for Palvella Therapeutics Stock

Analyst Ratings News

PROCanaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243

PROOppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232

PROWilliam Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday

PROHC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

PROStephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

People Also Watch

People Also Watch

PRO
Canaccord Genuity Maintains Buy on Palvella Therapeutics, Raises Price Target to $243

PRO
Oppenheimer Maintains Outperform on Palvella Therapeutics, Raises Price Target to $232

PRO
William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating

PRO
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246

PRO
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target